Abstract |
AIDS-associated Kaposi's sarcoma (KS) in eight patients was treated with the systemic application of liposomal doxorubicin (20 mg/m2 per cycle). After six cycles of treatment a significant regression of KS was observed in all patients. Tumour volume was reduced from 556 +/- 635 mm3 before therapy to 42 +/- 134 mm3 after therapy as determined by ultrasonography of selected tumours. Histological examination revealed a reduction of tumour-like structures and the absence of KS spindle cells in involved areas after therapy. In vitro experiments with KS-derived cell cultures, which most likely represent the KS spindle cells, suggested that liposomal doxorubicin may cause regression of KS via two different mechanisms: (i) by highly specific inhibition of KS spindle cell proliferation and (ii) by induction of monocyte chemoattractant protein-1 expression in KS spindle cells, which may result in increased recruitment of phagocytic cells (monocytes/macrophages) into the lesions. A cooperative action of both mechanisms may explain the high efficacy of liposomal doxorubicin in the treatment of AIDS-KS.
|
Authors | M Stürzl, C Zietz, B Eisenburg, F D Goebel, R Gillitzer, P H Hofschneider, J R Bogner |
Journal | Research in virology
(Res Virol)
1994 May-Aug
Vol. 145
Issue 3-4
Pg. 261-9
ISSN: 0923-2516 [Print] France |
PMID | 7800953
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Liposomes
- Pharmaceutical Vehicles
- Doxorubicin
|
Topics |
- Acquired Immunodeficiency Syndrome
(complications)
- Adult
- Cell Division
(drug effects)
- Doxorubicin
(administration & dosage)
- Fibroblasts
(drug effects, pathology)
- Gastrointestinal Neoplasms
(drug therapy, etiology, pathology)
- Humans
- Liposomes
- Lung Neoplasms
(drug therapy, etiology, pathology)
- Middle Aged
- Mouth Neoplasms
(drug therapy, etiology, pathology)
- Pharmaceutical Vehicles
- Sarcoma, Kaposi
(drug therapy, etiology, pathology)
- Tumor Cells, Cultured
(drug effects, pathology)
|